We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Otsuka Sues FDA Over Loss of Abilify Patent Protection

Otsuka Sues FDA Over Loss of Abilify Patent Protection

October 26, 2015

For the second time this year, Otsuka has sued the FDA for loss of patent protection for its schizophrenia drug Abilify — this time to reverse the agency’s approval of Alkermes’ Aristada.

Otsuka argues the FDA denied the brandmaker’s right to three years of exclusivity for its next-generation Abilify Maintena (aripiprazole) when it approved Aristada (aripiprazole lauroxil).

Alkermes has already launched Aristada in the U.S.

The FDA denied an Otsuka petition on Oct. 5, saying Aristada’s approval can’t be blocked by exclusivity applicable to Abilify Maintena because it contains a different active molecule. Otsuka maintains that it is the same molecule.

The Japanese drugmaker argues that the FDA committed “regulatory sleight of hand” in determining that Abilify Maintena and Aristada are different for purposes of exclusivity, but letting Aristada rely upon Otsuka’s aripiprazole safety and effectiveness data.

In May, Otsuka lost a lawsuit claiming the FDA knowingly removed its monopoly protection by extending Abilify’s pediatric indication for Tourette syndrome to adults, which the company had not sought. That decision cleared the way for the U.S. launch of Abilify knock-offs by Hetero Labs, Teva, Alembic Pharmaceuticals and Torrent Pharmaceuticals.

Otsuka Pharmaceutical v. Burwell et al.was filed in U.S. District Court for the District of Columbia. The FDA does not comment on pending litigation. Otsuka and Alkermes could not be reached for comment by press time. — Jonathon Shacat

Pharmaceuticals Commercial Operations

Upcoming Events

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

  • 08Mar

    Medical Device Cybersecurity: The Regulatory Landscape and How to Defend Your Practices During an Inspection

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Updates Smiths Medical CADD System Recall to Class I

  • Eisai’s New Alzheimer’s Drug Leqembi Hits the U.S. Market

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing